1. Introduction {#s0005}
===============

*Blastocystis* sp. inhabits the large intestine of humans and it is the most frequently observed enteric protist in Chile and throughout the world ([@bb0065]; [@bb0035]). *Blastocystis* sp. is subtyped through sequences of its small subunit ribosomal RNA (*18S SSU rDNA*) gene and classified as STs, being the most common worldwide the ST1, ST2 and ST3 subtypes ([@bb0110]; [@bb0105]). Subtyping of this enteric protist has been performed in South America, mainly in Argentina, Bolivia, Brazil, Colombia, Ecuador and Peru ([@bb0085]) but not yet in Chile.

The relationship of *Blastocystis* sp. and Inflammatory Bowel Syndrome (IBS) has been suggested in industrialized countries and in Chile ([@bb0030]). It has been described that ST1 and ST3 subtypes of *Blastocystis* sp. are frequently detected in IBS patients ([@bb0010]; [@bb0090]). However, the pathogenic role of this organism continues under study ([@bb0050]). Statistics of IBS prevalence in Chile is scarce but a diagnosis of this condition has increased in the last decade. By using the diagnostic criteria and management recommendations of Rome II, IBS was estimated to occur in 28,6% of the adult population of Santiago, the Metropolitan Region of Chile ([@bb0030]).

In order to investigate the putative involvement of *Blastocystis* sp. subtypes in IBS, we studied 37 IBS patients in Santiago, Chile for this protist, through its *SSU rDNA* subtyping and subtypes alleles. We also determined STs and their respective alleles in fecal samples of five Chilean individuals with blastocystosis that included two children and three adult members of the same family, who had no IBS symptoms.

2. Material and methods {#s0010}
=======================

2.1. Ethics statement {#s0015}
---------------------

This study was approved under the number 212--2015 by the Ethics Committee on Research in Human Beings of the Faculty of Medicine of the Universidad de Chile.

2.2. Samples and patient characterization {#s0020}
-----------------------------------------

Fecal samples of the 37 symptomatic participants of the IBS study group were collected for one year, from September 2017 to September 2018 in Santiago, Chile. All IBS symptomatic patients were adults (average age: 35 years-old) recruited following the Rome IV Diagnostic Criteria for IBS ([@bb0025]; [@bb0055]). Five fecal samples of three adults and two children with no IBS symptoms but *Blastocystis* sp. presence in a parasitological microscopically examination was used to determine in non-IBS carriers STs of *Blastocystis* sp. for preliminary comparative purposes. These fecal samples were originally collected in 2018 to detect intestinal parasites in a family group from Santiago and in a parasitological epidemiology survey in children done in La Serena city and donated to us by the respectively researchers.

Fecal samples were divided into two aliquots and transported in plastic containers to the laboratory of the Parasitology Unit in the Faculty of Medicine of the University of Chile for processing. One aliquot was fixed with sodium acetate-acetic acid-formalin (SAF) (Thermofisher Scientific, KS, USA) for microscopy examination and the other preserved in ethanol 70% for molecular diagnostic processing. All samples were stored at 4 °C until use.

2.3. Microscopy examination and molecular procedures {#s0025}
----------------------------------------------------

SAF fixed samples were examined by light microscopy at 40× (AXIO-Lab.A1, Zeiss, Germany) for *Blastocystis* sp. vacuolar forms (VF) detection. The corresponding positive samples preserved in ethanol were processed for DNA extraction as follows: Feces were concentrated using PARA-PAK (Meridian Inc., USA) and DNA extracted from 250 μl of concentrated feces using the QIAamp DNA Stool Mini Kit (QIAGEN, MD, USA) according to manufacturer protocol. The resulting DNA samples were stored at −20 °C until further processing. PCR was performed in a total volume of 25 μl containing 0.5 μM of each of the primers RD5 5′-ATC TGG TTG ATC CTG CCA GT-3′ and BhRDr 5′-GAG CTT TTT AAC TGC AAC AAC G-3′ ([@bb0095]), 1× GoTaq® Green Master Mix (Promega Corporation, WI, USA), 1--5 μl of DNA template, using the following program in the Applied Biosystems 2720 Thermal Cycler (Thermofisher Scientific, KS, USA): initial denaturation at 94 °C for 3 min, 35 cycles of, denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s, extension at 72 °C for 30 s and final extension at 72 °C for 5 min. Amplicons were analyzed by agarose 1% gel electrophoresis in 1× TAE (Thermofisher Scientific, KS, USA) and staining with GelRed® Nucleic Acid Gel Stain (Biotium, CA, USA). An amplicon of about 600 bp was generated in all *Blastocystis* sp. positive samples. PCR products were purified (Wizard® SV Gel and PCR Clean-Up System, Promega Corporation, WI, USA) and sent to an external facility for Sanger sequencing. Electropherograms were visualized and edited with MEGA 7.0 ([@bb0045]) and the resulting sequences were identified in GenBank® using BLAST (NHI U.S. National Library of Medicine). *Blastocystis* sp. identified sequences were then compared to sequences in *Blastocystis* sp. Subtype (*18S*) and Sequence Typing (MLST) database ([@bb0040]) for subtyping and identification of respective closest match alleles.

3. Results and discussion {#s0030}
=========================

*Blastocystis* sp. subtypes ST1, ST2 and ST4 were observed in the samples from IBS patients, while ST1, ST2, ST3 were identified in the non-IBS samples ([Table 1](#t0005){ref-type="table"}). Only an IBS patient presented the ST4 subtype. Interestingly, three of the non-IBS individuals were members of the same family but their samples presented three different *Blastocystis* sp. subtypes, ST1, ST2 and ST3. Representative partial sequences of each subtype of *Blastocystis* sp. Chilean isolates were uploaded to GenBank with accession numbers: MN403319, MN435628, MN435630, MN435631.Table 1*Blastocystis* sp. subtypes observed in individuals with and without inflammatory bowel syndrome from Chile.Table 1Patient conditionLocation (city)Age (years)Gender*Blastocystis* sp.SbtypeIBSSantiago34FemaleST1IBSSantiago28FemaleST1^1^IBSSantiago27FemaleST2^2^IBSSantiago44FemaleST4^3^AsymptomaticSantiago50MaleST1AsymptomaticSantiago45FemaleST2AsymptomaticSantiago25FemaleST3^4^AsymptomaticLa Serena2FemaleST2AsymptomaticLa Serena3MaleST3[^1]

The ST1, ST2 and ST3 subtypes found in Chile were also found in other surveyed South American countries ([@bb0085]), both in non-IBS individuals and IBS patients while the ST4 subtype was observed in Colombia ([@bb0085]), Brazil ([@bb0120]; [@bb0005]; [@bb0100]) and now in Chile, in an IBS patient. Subtype 4 was mainly detected in Europe, being identified in 74% of Danish patients infected by *Blastocystis* sp. and with symptoms of acute diarrhea ([@bb0115]), also, in Spain, this subtype was observed in the 94.1% of symptomatic patients with digestive manifestation surveyed in Valencia ([@bb0020]), and it also was detected in symptomatic humans in different communities of the northern region of this country ([@bb0080]).

All alleles: 2, 12, 34 and 42 we have detected here in respectively ST1, ST2, ST3 and ST4 *Blastocystis* subtypes have been previously described by [@bb0085] in several countries of South America and it is the allele often described in Europe for this subtype.

In this study, we found *Blastocystis* sp. in 4 out 37 (10.81%) samples from IBS patients, detecting vacuolar forms of *Blastocystis* sp. by using conventional microscopy. It was previously reported that this diagnostic method have low sensitivity compared with in-vitro culture and molecular diagnostic approach, but it has high specificity for detecting this protist in biological samples ([@bb0015]), this can be a potential bias of our study trying to determine an epidemiological vision of the prevalence of blastocystosis in symptomatic or asymptomatic individuals. The number of IBS patients found positive for this eukaryote is low compared to the frequency determined in the non-IBS population in Chile ([@bb0060]; [@bb0070]). Such low frequency has been previously reported in developing nation environment ([@bb0075]), differently to observations in European countries where *Blastocystis* sp. presence in IBS patients was more frequent than in non-IBS controls ([@bb0125]). More studies are necessary to clarify this discrepancy. The high global frequency of this eukaryotic microbe in humans is a stimulating reason for additional studies to better define aspects of its diagnosis, pathogenicity and epidemiology.
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[^1]: *Blastocystis* sp. Subtypes and closest match alleles in Chilean human isolates. (Genbank accession numbers: ^1^*MN435630*; ^*2*^*MN435628*; ^*3*^*MN403319*; ^*4*^*MN435631*).
